M. Javad Aman

Employment

• Integrated Biotherapeutics, Inc. Chief Scientific Officer
  2007 - 2015
• US Army Medical Research Institute of Infectious Diseases Staff Scientist / Principal Investigator
  2000 - 2007
• University of Virginia Post-doctoral Fellow
  1998 - 2000
• National Institutes of Health Post-doctoral fellow
  1994 - 1998

Education

Education history is unavailable.

Projects & Funding

Projects & funding information is unavailable.

Publications (14)

• Data from Targeting RET Solvent-Front Mutants with Alkynyl Nicotinamide-Based Inhibitors
  2025 DOI: 10.1158/1535-7163.c.6604950
  +Save
• Supplementary Data from Targeting RET Solvent-Front Mutants with Alkynyl Nicotinamide-Based Inhibitors
  2025 DOI: 10.1158/1535-7163.30733843
  +Save
• Data from Targeting RET Solvent-Front Mutants with Alkynyl Nicotinamide-Based Inhibitors
  2023 DOI: 10.1158/1535-7163.c.6604950.v2
  +Save
• Supplementary Data from Targeting RET Solvent-Front Mutants with Alkynyl Nicotinamide-Based Inhibitors
  2023 DOI: 10.1158/1535-7163.23274979.v1
  +Save
• Supplementary Data from Targeting RET Solvent-Front Mutants with Alkynyl Nicotinamide-Based Inhibitors
  2023 DOI: 10.1158/1535-7163.23274979
  +Save
• Targeting RET Solvent-Front Mutants with Alkynyl Nicotinamide-Based Inhibitors
  Molecular Cancer Therapeutics 2023 DOI: 10.1158/1535-7163.MCT-22-0629
  +Save
• Data from Targeting RET Solvent-Front Mutants with Alkynyl Nicotinamide-Based Inhibitors
  2023 DOI: 10.1158/1535-7163.c.6604950.v1
  +Save
• Supplementary Data from Targeting RET Solvent-Front Mutants with Alkynyl Nicotinamide-Based Inhibitors
  2023 DOI: 10.1158/1535-7163.22651725.v1
  +Save
• Supplementary Data from Targeting RET Solvent-Front Mutants with Alkynyl Nicotinamide-Based Inhibitors
  2023 DOI: 10.1158/1535-7163.22651725
  +Save
• The sphingosine kinase 1 activator, K6PC-5, attenuates Ebola virus infection
  iScience 2021 DOI: 10.1016/j.isci.2021.102266
  +Save